Xenon Pharmaceuticals Inc. (XENE) Income Statement

The absence of revenue in most quarters, combined with a single $7.5M recognition, suggests that collaboration milestones rather than recurring commercial sales drive reported income. Growth rates computed from these isolated periods are not meaningful and should not be extrapolated. Investors should treat revenue as a partnership-health indicator and monitor the timing of future milestone tranches.

The near doubling of R&D over roughly two years is consistent with the transition of XEN1101 into large Phase 3 execution, where CRO and patient recruitment costs scale. SG&A has been comparatively stable near $22M to $24M per quarter, indicating limited overhead expansion. The cost structure is therefore heavily program-driven, and the trajectory of R&D spending is the primary determinant of operating losses.

Operating losses have grown in lockstep with R&D, indicating negative operating leverage in the sense that costs are rising without a scaling revenue base. The business has no mechanism within the reported data to absorb incremental spend, so each step-up in trial activity directly deepens the loss. This structure implies continued reliance on external capital until partnership or commercial revenue becomes material.